Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial

Authors

Catherine G Derington
Adam P Bress
Andrew E Moran
William S Weintraub
Jennifer S Herrick
William C Cushman
Ian M Kronish
Barry Stults
Daichi Shimbo
Paul Muntner
Tom Greene
Jeffrey T Bates
Tara I Chang
Lois Anne Katz
Shakaib U Rehman
Christianne L Roumie
Leonardo Tamariz
Jordan B King

Publication Date

3-1-2023

Journal

Hypertension

DOI

10.1161/HYPERTENSIONAHA.122.20373

PMID

36519451

PMCID

PMC9931643

PubMedCentral® Posted Date

3-1-2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Keywords

Humans, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Pressure, Calcium Channel Blockers, Hypertension, Thiazides, hypertension, blood pressure, antihypertensive

Abstract

BACKGROUND: Describing the antihypertensive medication regimens used in the SPRINT (Systolic Blood Pressure Intervention Trial) would contextualize the standard and intensive systolic blood pressure (SBP) interventions and may inform future implementation efforts to achieve population-wide intensive SBP goals.

METHODS: We included SPRINT participants with complete medication data at the prerandomization and 12-month visits. Regimens were categorized by antihypertensive medication class. Analyses were stratified by treatment group (standard goal SBPHg).

RESULTS: Among 7860 participants (83.7% of 9361 randomized), the median number of classes used at the prerandomization visit was 2.0 and 2.0 in the standard and intensive groups (

CONCLUSIONS: SPRINT investigators favored combining ACEs or ARBs, thiazide diuretics, and calcium channel blockers to target SBPHg, compared to ACE/ARB monotherapy to target SBPHg.

REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT01206062.

Comments

Associated Data